---
title: "Liraglutide"
canonical_url: https://peptidelibrary.app/library/liraglutide
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Liraglutide

Liraglutide (also called Victoza or Saxenda) is an FDA-approved daily GLP-1 agonist. Liraglutide is a GLP-1 analog with a single amino-acid substitution and a sixteen-carbon fatty acid attached through a glutamate spacer.

Also known as: Victoza, Saxenda, NN2211.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: FDA-approved daily GLP-1 agonist
- Mechanism class: GLP-1 Agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Liraglutide is a GLP-1 analog with a single amino-acid substitution and a sixteen-carbon fatty acid attached through a glutamate spacer. The acyl chain drives reversible binding to serum albumin and promotes self-association at the injection site, which together slow absorption and clearance and extend the half-life from minutes to roughly thirteen hours, allowing once-daily administration. At the GLP-1 receptor it enhances glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, and slows gastric emptying. Appetite reduction is mediated centrally, through GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem, which is why the weight effect is separate from the glycaemic one.

Targets: GLP-1 receptor.

Origin: Acylated human GLP-1 analog (Novo Nordisk).

## Properties

- Molecular formula: C172H265N43O51
- Molecular weight: 3,751.2 g/mol
- CAS number: 204656-20-2
- Half-life: Approximately 13 hours
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 1
- Controlled human trials: 1
- Preclinical sources: 0

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. SAXENDA (liraglutide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with obesity or overweight with a weight-related comorbidity, and patients aged 12+ over 60 kg with obesity. Chronic weight management [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143)
2. LIRAGLUTIDE injection — FDA prescribing information (Meitheal Pharmaceuticals), DailyMed. Regulatory label (FDA), human. Population: Per the referenced listed drug's approved indications. Same indications as the reference product [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0efc3a89-211a-4496-baab-e8265e07de2b)
3. NCT01117350 — Efficacy Assessment of Insulin Glargine Versus Liraglutide After Oral Agent Failure. Controlled human trial. Population: Adults with type 2 diabetes (n=978). Glycaemic control versus insulin glargine after oral therapy failure [Source](https://clinicaltrials.gov/study/NCT01117350)

### Registered trials

- [NCT01117350](https://clinicaltrials.gov/study/NCT01117350)

## Safety

Side effects: Nausea; Vomiting; Diarrhea; Gallbladder events.

Risks: MTC/MEN2 boxed warning; Pancreatitis rare.

Human safety basis: FDA prescribing information

## Regulatory status

Liraglutide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### Is Liraglutide FDA approved?

Yes. Liraglutide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Liraglutide?

Reported half-life for Liraglutide is ~13 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Liraglutide banned in sport?

Liraglutide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Liraglutide?

Compounds most often compared with Liraglutide include Semaglutide, Tirzepatide, Retatrutide and Exenatide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Saxenda label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf)
- [Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial — Obesity (Silver Spring), 2022](https://pubmed.ncbi.nlm.nih.gov/35894080/)
- [Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes — N Engl J Med, 2016](https://pubmed.ncbi.nlm.nih.gov/27295427/)
- [Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial — Diabetes Care, 2016](https://pubmed.ncbi.nlm.nih.gov/27506222/)
- [Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial — JAMA, 2015](https://pubmed.ncbi.nlm.nih.gov/26284720/)
- [Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review — Cureus, 2025](https://pubmed.ncbi.nlm.nih.gov/40206909/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
